Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2008 financial results after the NASDAQ Global Market closes on Tuesday, August 5, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the second quarter 2008 financial results and to provide a corporate update.

The conference call may be accessed by dialing 877.419.6590 for domestic callers and 719.325.4872 for international callers. Please specify to the operator that you would like to join the "Arena Second Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independentl
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ... Bina Technologies, Inc. (Bina), a privately held company ... , USA. Bina provides a big data platform ... sequencing (NGS) data. Bina,s proprietary on-market Genomic Management ... academic researchers to perform fast and scalable analyses ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... March 7 On Thursday, March 13, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... call to discuss the company,s 2007 fourth,quarter achievements ... Numbers Thursday, March 13 8:30 a.m. ...
... team of researchers from the departments of macromolecular science ... of Engineering and the Louis Stokes Cleveland Department of ... a new type of polymer that displays chemoresponsive mechanic ... to soft plastic and vice versa in seconds when ...
... March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... to the,Company,s Board of Directors., "As the ... of the former Bayer Diagnostics and Diagnostic Products,Corporation, ... our Board," said Dr.,Paul Walker, President and CEO ...
Cached Biology Technology:Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 2Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 3Spectral appoints Anthony Bihl to Board of Directors 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... (GIVI) have identified a previously unknown function of APOBEC3G (A3G), ... lead to new approaches for controlling HIV infection. , ... of the National Academy of Sciences, USA. , The research, ... C. Greene, MD, PhD, explains why CD4 T cells ?the ...
... or stroke, paramedics, doctors, and nurses follow standardized protocols for ... odds for a full recovery. That's not the case if ... be fatal within a few hours and is often not ... new, multicenter research consortium, called Protocolized Care for Early Septic ...
... individual's immune system controls HIV during the earliest phases ... versions of key immune-system molecules called HLA Class I ... fragments of viral protein those molecules display to the ... a report in the November issue of PLOS Medicine, ...
Cached Biology News:Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
... of monoclonal antibody reactive against the complex IV ... highest in growing cultured cells. SURF1 is an ... is thought to participate in the folding of ... subunit. Mutations of SURF1, particularly ones that result ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: